Daniel Morgensztern
MD
Professor of Medicine and Section Chief, Thoracic Oncology
👥Biography 个人简介
Dr. Daniel Morgensztern is a thoracic oncologist who has participated in pivotal trials combining savolitinib with osimertinib to overcome MET-amplification-driven resistance to third-generation EGFR inhibitors. He is active in evaluating MET inhibitors across settings including METex14 primary tumors and MET-mediated acquired EGFR resistance. His research spans early-phase clinical trials of novel lung cancer therapeutics.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Daniel Morgensztern 的研究动态
Follow Daniel Morgensztern's research updates
留下邮箱，当我们发布与 Daniel Morgensztern（Washington University School of Medicine in St. Louis）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment